Objective: The purpose of this article is to update current data on immunotherapy in uro-oncology. Material and methods: Synthesis of data from recent literature and data presented at national and international conferences on immunotherapy in urological cancers. Results: Current immunotherapies restore the anti-tumor immunity, by blocking immunity-negative feedback checkpoints. In metastatic renal cell carcinoma and bladder carcinoma, immunotherapy has first shown a significant survival benefit in second-line, and more recently in first-line for kidney cancer. Trials are currently ongoing in adjuvant and neoadjuvant settings. In prostate cancer, there is little data and immunotherapy seems to benefit a limited subgroup of patients. Conclusion: Immunotherapy is a key treatment in kidney and bladder cancer. In the future, the identification of predictive markers should allow us to better select patients responding to immunotherapy.